I
Intelligent Retinal Imaging Systems
IRIS preventative screening for Diabetic Retinopathy is as simple and quick as taking a patient's blood pressure or stepping on a scale
About Intelligent Retinal Imaging Systems
IRIS (Intelligent Retinal Imaging Systems) operates in the healthcare technology sector, specializing in retinal screening solutions. The company provides cloud-based diagnostic software that enables healthcare practitioners to detect vision-threatening retinal diseases, particularly diabetic retinopathy. IRIS serves healthcare providers, including hospitals and clinics, aiming to improve patient outcomes through early detection and management of chronic eye conditions. The business model revolves around a subscription-based service, where clients pay for access to the diagnostic platform and associated services. Revenue is generated through these subscriptions and additional fees for advanced features or higher usage tiers. By leveraging telemedicine and a bi-directional EHR (Electronic Health Record) interface, IRIS facilitates seamless integration into existing healthcare systems, enhancing efficiency and accuracy in retinal evaluations. The market for IRIS includes healthcare providers focused on chronic disease management and preventive care, particularly in diabetic patient populations. The company has demonstrated significant growth, as evidenced by its ranking on the Inc. 500 list with a three-year sales growth of 955%.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2011
- Headquarters
- Pensacola, United States
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 67.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, DT and LS, science-based
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Computer Vision
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2025 | $0 | — | Topcon Healthcare | ↗ |
| EARLY VCEquity / VC | Nov 2019 | $4.3M | $17M | Undisclosed | — |
Growth signals
Latest recorded traffic for Intelligent Retinal Imaging Systems is 6.7K monthly website visits, up 31.4% over the last three months. Intelligent Retinal Imaging Systems's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- BVBallast Point Ventures
Providence Ventures
Other known investors2 additional known investors
Topcon Healthcare
Institute for Commercialization of Florida Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intelligent Retinal Imaging Systems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intelligent Retinal Imaging Systems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.